INTRODUCTION AND OBJECTIVES:
The advent of multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy platforms have improved the diagnostic accuracy of prostate biopsies otherwise limited in standard ultrasound (US)-guided techniques. Electromagnetically (EM) tracked transperineal MR/US fusion guided prostate biopsy (tpFBx) (Invivo, Gainesville, FL) is a novel fusion biopsy system for targeting suspicious lesions on mpMRI of the prostate. In the largest series to date to critically evaluate the EM-tracked (tpFBx) system, we sought to determine if there is a difference in the ability of the biopsy platform to detect cancer based on target lesion size.
METHODS: A total of 52 men who had undergone mpMRI of the prostate to identify regions suspicious for prostate cancer (PCa) were included. Images were interpreted using Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). A total of 75 suspicious lesions were identified, all of which were sampled by EMtracked tpFBx. Lesions were subdivided on the basis of volume (L x W x H x p/6): > 0.2 cc, 0.2 -0.5 cc, 0.5 -1.0 cc, > 1.0 cc. Epstein criteria for clinically significant (CS) PCa was used (tumor volume > 0.5 cc and/or Gleason Score (GS) > 6). Fisher's exact test was used to compare the targeted lesion volume groups with respect to CDR, CDR of CS PCa, and GS risk stratification.
RESULTS: The CDR per lesion was 56.0% (42/75). Median age was 67.8 years and median prostate specific antigen at biopsy was 7.3 ng/ml. There was no difference in CDR across the groups after stratifying by GS risk level (Low, Intermediate, or High) (p¼.23). The ability to target suspicious lesions and detect cancer was unaffected by volume of the lesion (p¼.11). A subgroup analysis of lesions < 0.2 cc (n¼22) and 0.2 cc to 0.5 cc (n¼24) showed no statistical difference with regards to CS-PCa detection (p¼.74).
CONCLUSIONS: The tpFBx platform does not demonstrate degradation in performance of cancer detection when targeting prostate lesions of varying volumes. This was true for all diagnosed cancers and after stratifying by GS risk. Though the size of the series is limited, these results support the diagnostic value of mpMRI in conjunction with this novel tpFBx system to accurately target suspicious areas and identify CS disease regardless of lesion size and should be evaluated further.
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MP18-04 ROLE OF PI-RADS VERSION 2 FOR PREDICTION OF UPGRADING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE BIOPSY GLEASON SCORE 6
Song Wan*, Chan Kyo Kim, Young Hyo Choi, Hyun Woo Chung, Chung Un Lee, Jun Phil Na, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Accurate prediction of Gleason score (GS) after radical prostatectomy (RP) is important to determine treatment plans. However, 20-60% of patients with biopsy GS 6 are upgraded to GS 7 or more postoperatively. In this study, we evaluated whether Prostate Imaging Report and Data System version 2 (PI-RADSv2) has a role to predict upgrading after RP for patients with biopsy GS 6 METHODS: We retrospectively reviewed 443 patients who underwent magnetic resonance imaging (MRI) and RP for prostate cancer with biopsy GS 6 between January 2011 and December 2013. Preoperative clinical parameters (prostate specific antigen [PSA], prostate volume, PSA density, number of positive core and maximum percentage of cancer per core), PI-RADS v2 score and pathologic GS were examined. Multivariate logistic regression was used to analyze predictive factors of upgrading after RP. Receiver operating characteristic (ROC) curves were used to analyze the predictive accuracies of multivariate logistic regression models and areas under the curves (AUCs) of ROC curves were compared.
RESULTS: Of 443 patients with biopsy GS 6, GS upgrading was identified in 297 (67.0%) patients (GS7, n¼273 and GS8-10, n¼24) following RP. PI-RADS v2 score 1-3, and 4-5 were identified in 157 (25.4%) and 286 (64.6%) patients, and upgrading rate after RP were 54.1% and 74.1%, respectively (p < 0.001). On multivariate analysis, PSA density > 0.16 ng/ml2, number of positive core ¼ 2, maximum % cancer/core >20% and PI-RADS v2 score 4-5 were predictive factors of upgrading following RP (all p < 0.05). When predictive accuracies of multivariate models were compared using AUC from ROC curves, model 2 (PI-RADS v2 score 4-5 along with model 1) was found to have significantly higher accuracy then model 1(PSA density > 0.16 ng/ml2, number of positive core ¼ 2 and maximum % cancer/core >20%) (0.729 vs 0.703, p ¼ 0.041) CONCLUSIONS: PSA density > 0.16 ng/ml2, number of positive core ¼ 2 and maximum percentage of tumor length in a core > 20% are independent predictors of GS upgrading as preoperative variables. PI-RADSv2 4-5 confer an increased risk for GS upgrading that it may be used as a preoperative image tool to establish treatment decision.
